Ionis· @ionispharma · X·· 2026-07-13AI 评分38
AI 导读
今天，我们宣布，首位受试者已在 1-2 期 ASCEND 研究中接受给药，该研究评估我们针对 Dravet 综合征患者的在研 RNA 靶向药物。了解更多：https://bit.ly/4aLyFfh $IONS #DravetSyndrome #Dravet
正文
Today, we announced that the first participant has been dosed in the Phase 1-2 ASCEND study evaluating our investigational RNA-targeted medicine for people living with Dravet syndrome. Learn more: https://bit.ly/4aLyFfh
$IONS
#DravetSyndrome #Dravet
来源：Ionis · x.com